Serina Therapeutics, Inc. SER
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company's proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130.0K | $56.0K | $3.2M | $34.0K | $144.0K | $361.0K | $1.7M | $1.4M | $1.4M | — |
| Cost of revenue | — | — | $40.0K | $13.0K | $19.0K | $26.0K | $244.0K | $364.0K | $168.0K | — |
| Gross profit | — | — | $102.0K | $21.0K | $125.0K | $335.0K | $1.5M | $1.0M | $1.2M | — |
| R&D | $13.2M | $7.5M | $2.4M | $1.0M | $1.5M | $3.7M | $5.9M | $5.8M | $5.8M | — |
| SG&A | $11.0M | $9.6M | $3.9M | $6.0M | $6.7M | $6.7M | $8.1M | $5.6M | $3.9M | — |
| Total operating expenses | $24.2M | $17.1M | $6.3M | $7.0M | $8.2M | $10.4M | $14.0M | -$12.3M | $9.7M | — |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$7.0M | -$7.9M | -$10.1M | -$12.6M | -$11.2M | -$6.7M | — |
| Interest expense | $213.0K | $526.0K | $558.0K | $3.3M | $1.1M | — | — | — | — | — |
| Pre-tax income | -$19.2M | -$11.2M | $5.3M | $10.5M | $8.7M | -$11.1M | -$12.2M | -$7.7M | — | — |
| Income tax | $18.0K | $0 | $0 | — | — | $150.0K | $148.0K | — | — | — |
| Net income | -$19.2M | -$11.2M | $5.3M | -$10.5M | -$8.7M | $2.0M | -$12.2M | -$7.5M | -$6.6M | — |
| EPS, basic | -1.91 | -1.51 | 2.36 | -9.70 | -0.23 | — | — | — | — | — |
| EPS, diluted | -1.91 | -1.51 | 0.73 | -9.70 | -0.23 | -0.29 | -0.33 | -0.21 | -0.21 | — |
| Shares, diluted (wtd. avg.) | 10.2M | 7.4M | 7.4M | 1,079 | 37.9M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.1M | $3.7M | $7.6M | $645.0K | $584.0K | $527.0K | $2.4M | $6.7M | $7.4M | $259.0K |
| Receivables | — | — | $57.0K | $4.0K | $25.0K | $326.0K | $363.0K | $131.0K | $107.0K | — |
| Total current assets | $6.1M | $5.7M | $7.6M | $2.5M | $2.2M | $2.3M | $4.1M | $7.9M | $7.6M | — |
| Property, plant and equipment | $465.0K | $501.0K | $573.0K | — | — | — | $1.1M | $90.0K | $129.0K | — |
| Other intangibles | — | — | $607.0K | $738.0K | $870.0K | $1.6M | $2.2M | $2.7M | $1.9M | — |
| Total assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M | $3.9M | $7.4M | $10.7M | $9.6M | — |
| Accounts payable | $1.9M | $744.0K | $580.0K | $568.0K | $193.0K | $761.0K | $420.0K | $150.0K | $75.0K | — |
| Total current liabilities | $3.6M | $2.4M | $1.4M | $10.1M | $9.0M | $5.4M | $3.3M | $2.4M | — | — |
| Long-term debt | — | — | — | $18.1M | $13.2M | — | — | — | — | — |
| Total liabilities | $7.0M | $6.2M | $4.9M | $20.6M | $15.0M | $9.3M | $4.8M | $2.4M | $1.3M | — |
| Retained earnings | -$63.5M | -$44.3M | -$33.2M | -$116.2M | -$105.7M | -$97.1M | -$86.2M | -$74.1M | -$66.6M | — |
| Total equity | -$37.0K | $641.0K | -$32.3M | -$37.8M | -$11.9M | -$5.4M | $2.6M | $8.2M | $8.3M | -$22.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.0M | -$17.1M | -$2.5M | -$5.9M | -$7.9M | -$7.8M | -$10.2M | -$8.0M | -$6.3M | — |
| Depreciation and amortisation | $100.0K | $100.0K | — | — | — | $699.0K | $91.0K | $58.0K | $165.0K | — |
| Stock-based compensation | — | $2.6M | $25.0K | $760.0K | $999.0K | $909.0K | $1.9M | $1.3M | $114.0K | — |
| Capital expenditure | $59.0K | $22.0K | $504.0K | — | — | $20.0K | $641.0K | $21.0K | $1.0K | — |
| Investing cash flow | -$59.0K | -$22.0K | -$504.0K | — | $666.0K | -$20.0K | -$361.0K | $1.3M | $5.0K | — |
| Financing cash flow | $17.4M | $13.2M | $10.1M | $6.0M | $7.2M | $6.0M | $6.3M | $6.0M | $13.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001708599-26-000029.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.4M | $1.4M | $1.7M | $361.0K | $144.0K | $34.0K | $3.2M | $56.0K | $130.0K |
| Gross profit | — | $1.2M | $1.0M | $1.5M | $335.0K | $125.0K | $21.0K | $102.0K | — | — |
| Net income | — | -$6.6M | -$7.5M | -$12.2M | $2.0M | -$8.7M | -$10.5M | $5.3M | -$11.2M | -$19.2M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Charter or fiscal year changed Item 5.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |